Alfresa Pharma to Become Distributor of Anafranil Antidepressant.Tokyo, Japan, Oct 15, 2005 - (JCNN JCNN Japan Corporate News Network ) - Alfresa Holdings and Novartis Pharma jointly announced on October 11 that they have agreed on the production and distribution of Anafranil A·naf·ra·nil A trademark for the drug clomipramine. clomipramine hydrochloride Anafranil, Apo-Clomipramine (CA), Gen-Clomipramine (CA), Novo-Clopamine (CA) Pharmacologic class: , Novartis Pharma's proprietary antidepressant antidepressant, any of a wide range of drugs used to treat psychic depression. They are given to elevate mood, counter suicidal thoughts, and increase the effectiveness of psychotherapy. agent. Under the agreement terms, Novartis Pharma will transfer the production and distribution to Alfresa Pharma, a group company of Alfresa Holdings, by January 2006. Until then, Novartis Pharma continues to manufacture and promote the agent. With this move, Alfresa Pharma aims to concentrate its resources on central nervous system drugs while Novartis Pharma will focus more on its core business. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion